CompletedPhase 2

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

United States36 participantsStarted 2022-09-01

Plain-language summary

The purpose of this research is to study the effectiveness and safety of the medication PB in slowing the frequent urination related to tolvaptan as long-term treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), or frequent urination related to inherited nephrogenic diabetes insipidus as an inherited condition or as an acquired condition from prior treatment with lithium.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ADPKD(as delineated in cohort 1)
✓. Congenital NDI (as delineated in cohort 1)
✓. Lithium-induced NDI (as delineated in cohort 1)

What they're measuring

Change in urine osmolality

Timeframe: Baseline, 30 days

Trial details

NCT IDNCT05190744

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-08

View on ClinicalTrials.gov More Autosomal Dominant Polycystic Kidney Disease trials